Inclusion of Risdiplam in Rare Diseases Fund to Treat Spinal Muscular Atrophy
- Mr Ong Hua Han asked whether the Rare Diseases Fund (RDF) could include risdiplam for spinal muscular atrophy, citing data showing motor function improvements after treatment.
- The Senior Parliamentary Secretary explained that the RDF, a charity fund with government matching, lists treatments based on clinical effectiveness and donor funding, and that MOH will separately review spinal muscular atrophy treatments for mainstream subsidies.
- Mr Ong followed up by asking if the RDF could modify its eligibility criteria to include medicines that enhance quality of life even without evidence of life extension.
- The response noted that the RDF’s expert panel decides on covered medicines, and eligibility depends on sufficient funds to support all known patients for that treatment.